VIRPAX PHARMACEUTICALS, INC.
CIK 0001708331
Revenue (TTM)
—
FY Feb 2025
Net Income (TTM)
−$14.67M
+20.6% YoY
FY Feb 2025
EPS Diluted (TTM)
−$10.05
+78.1% YoY
FY Feb 2025
Gross Margin
—
FY Feb 2025
Operating Margin
—
FY Feb 2025
Net Margin
—
FY Feb 2025
Free Cash Flow (TTM)
—
FY Feb 2025
Cash
$41.71M
FY Feb 2025
Total Debt
$1.07M
FY Feb 2025
Shares Outstanding
26.56M sh
FY Feb 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.